Dr. Salome Arobelidze, MD

Dr. Arobelidze practices at Cleveland Clinic Main Campus in Cleveland, Ohio, part of The Cleveland Clinic Foundation.

Dr. Arobelidze's NPI, 1710322813, was assigned on May 2, 2013. Dr. Arobelidze holds Ohio license 127582.

Dr. Arobelidze's primary practice is Cleveland Clinic Main Campus, at 9500 Euclid Avenue, Cleveland, OH 44195 in Cuyahoga County. The practice phone is (216) 952-9829.

Dr. Arobelidze's primary practice is Cleveland Clinic Main Campus in Cleveland, Ohio, part of The Cleveland Clinic Foundation. Dr. Arobelidze is also affiliated with Fairview Hospital. The medical group on file is Cleveland Clinic. Dmand AI also links Dr. Arobelidze to 2 more clinical labs, each named with a free account. Dr. Arobelidze's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Arobelidze practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Arobelidze's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Arobelidze is licensed in Ohio.

CMS data shows 308 Medicare services from Dr. Arobelidze across 3 procedure codes in 2024, for 114 Medicare patients. Medicare paid $22,722 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 114 Medicare patients who saw Dr. Arobelidze in 2024. The largest group is 65 to 74, with 38 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 29% are also on Medicaid. Their average risk score is 3.44, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Arobelidze's median patient age at 62, with 55% women.

In 2024, Dr. Arobelidze wrote 154 Medicare Part D claims for 63 patients. 92% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $67 in total drug cost. In 2022, CMS named 14 claims across 1 drug.

Dr. Arobelidze accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 5 papers to Dr. Arobelidze, published from 2017 to 2023. 2017 was the busiest year, with 2. Dr. Arobelidze has published most often in Cureus. Dr. Arobelidze's most frequent co-authors are Hamed A. Daw, MD, Timothy P. Spiro, MD and Yee Chung C. Cheng, MD.

CMS Open Payments shows 12 general payments to Dr. Arobelidze from 7 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Gilead Sciences, Inc. paid the most, $121.